PTO/SB/30 (10-01)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PLANEN REQUEST

FOR

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to: **Commissioner for Patents Box RCE** Washington, DC 20231

displays a valid OMB condent	
09/806,925	_
Jun 20 2001	_
Araki	_
1651	_
R. Davis	
MTSIL-1001US	_
	09/806,925 Jun. 20, 2001 Araki 1651 R. Davis

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8,

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility of plant application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility of plant application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility of plant application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.
1995, or to any design application. See instruction in the second in the
1. Submission required under 37 CFR 1.114
a. Previously submitted i. Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on
b. Enclosed i. Amendment/Reply ii. Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS) iv. Other
2. Miscellaneous a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
b. Other 3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. i. RCE fee required under 37 CFR 1.17(e) ii. Extension of time fee (37 CFR 1.136 and 1.17)
b. Check in the amount of \$740.00 enclosed c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not warm and authorization on PTO-2038.
be included on this form. Provide credit data into
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED
Name (Print /Type) Keyin J. Dunleavy Registration No. (Attorney/Agent) 32,024 Signature Date December 2002
A TRANSMISSION
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as frst class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.
Name (Print/Type) Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



DOCKET NO.: MTSU-1001US 1/6/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Araki et al.

Serial No.: 09/806,925.

Group No.: 1651

Filed:

June 20, 2001

Examiner: R. Davis

For:

Preventative or Remedies for

Infection, Anti-Endotoxin Agents, :

Vaccine Adjuvants and Growth

Promoters

RECEIVED

DEC 1 7 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner for Patents BOX RCE Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-identified application, please amend the above-captioned patent application as follows. For the convenience of the Examiner, all the currently pending claims are attached below.

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Date: December 4, 2002

I hereby certify that this paper, along with any document or paper referred to as being attached or enclosed, is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 in an envelope addressed to the Commissioner for Patents, BOX RCE, Washington, D.C. 20231.

Name of person mailing correspondence

Signature of person mailing correspondence